Inhibitory Learning-Based Exposure for Panic Disorder

Phase-Based Progress Estimates
Panic Disorder+1 MoreInhibitory Learning-Based Exposure - Behavioral
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will compare two different approaches to exposure therapy to see which is more effective in reducing fear and anxiety in people with social anxiety disorder or panic disorder.

Eligible Conditions
  • Panic Disorder
  • Social Anxiety Disorder

Treatment Effectiveness

Study Objectives

2 Primary · 12 Secondary · Reporting Duration: Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)

Week 10
Behavioral Avoidance Test (BAT)
Change in fear extinction generalization as measured by heart rate.
Implicit Fear Association Test
Week 24
Anxiety Sensitivity Index (ASI-3)
Positive and Negative Affect Schedule (PANAS 20 item)
Probability and Cost Questionnaire
Sheehan Disability Scale (SDS)
Week 24
Change in clinician-rated severity of social anxiety or panic disorder
Change in self-reported symptom severity of social anxiety or panic disorder
Week 9
Change in fear extinction generalization as measured by expectancy of unconditional stimuli during conditional stimuli presentation.
Change in fear extinction generalization as measured by skin conductance.
Week 12
Change in fear extinction generalization as measured by hear rate.
Week 24
Panic Disorder Severity Scale-Self Report (PDSS-SR)

Trial Safety

Trial Design

2 Treatment Groups

Habituation-Based Exposure
1 of 2
Inhibitory Learning-Based Exposure
1 of 2

Active Control

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: Inhibitory Learning-Based Exposure · No Placebo Group · N/A

Inhibitory Learning-Based Exposure
Experimental Group · 1 Intervention: Inhibitory Learning-Based Exposure · Intervention Types: Behavioral
Habituation-Based Exposure
ActiveComparator Group · 1 Intervention: Habituation-Based Exposure · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,415 Previous Clinical Trials
6,763,147 Total Patients Enrolled
Michelle G Craske, PhDPrincipal InvestigatorUniversity of California, Los Angeles
2 Previous Clinical Trials
235 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Zoom treatment sessions after March 2020 due to COVID-19.
You must be age 18 to 65.
You are either stabilized on psychotropic medications or medication-free.

Who else is applying?

What state do they live in?
How old are they?
18 - 6550.0%
What site did they apply to?
University of California, Los Angeles100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%
How many prior treatments have patients received?